LONDON (Reuters) – Britain’s recommendation against giving the Oxford-AstraZeneca COVID-19 vaccine to those aged under 30 due to the risk of blood clots will have a negligible impact on the vaccine programme, England’s deputy chief medical officer Jonathan Van-Tam said.
“Because of our supply situation in relation to alternative vaccines, the effect on the timing of our overall programme should be zero or negligible,” he said at a briefing on Wednesday.
(Reporting by Guy Faulconbridge and Kate Holton, Writing by Paul Sandle; editing by James Davey)
